Breaking news

Novartis Acquires Blackstone’s Anthos Therapeutics For Up To $3.1 Billion To Strengthen Cardiovascular Portfolio

by THEFUTURE.TEAM

February 11, 2025

Swiss pharmaceutical giant Novartis has struck a deal to acquire Anthos Therapeutics, a biopharma company majority-owned by Blackstone’s drug development arm, for up to $3.1 billion. The acquisition is aimed at bolstering Novartis’ presence in the cardiovascular sector, a key focus for the company as its blockbuster heart failure drug Entresto faces patent expiration this year.

Founded in 2019 by Blackstone’s Life Sciences division and Novartis, Anthos was created to develop abelacimab, a promising treatment designed to prevent strokes and prevent recurring blood clots. This transaction underscores Novartis’ commitment to cardiovascular treatments, which is one of five critical therapeutic areas the company is prioritizing.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

The deal, which is expected to close by mid-2025, marks a significant step in the evolving partnership between a major pharmaceutical company and private equity, a model that has gained traction in the industry. Novartis will pay an initial $925 million, with potential additional payments up to $2.15 billion, contingent on the successful development of the therapy.

This marks the largest sale of a majority-owned company by Blackstone’s Life Sciences division to date. In December 2023, Blackstone was exploring the sale of Anthos, and the current deal brings the partnership to a close.

Abelacimab is part of a new class of anticoagulants known as factor XI inhibitors, designed to potentially replace established blood thinners like Eliquis (Bristol Myers-Squibb and Pfizer) and Xarelto (Johnson & Johnson and Bayer), both of which are billion-dollar sellers. Other major companies in the factor XI race include Bristol-Myers Squibb and Johnson & Johnson, who are advancing a similar drug candidate, as well as Merck & Co, which is progressing with a mid-stage development candidate. Bayer, meanwhile, faced a setback in 2023 with its factor XI drug.

Nicholas Galakatos, Chairman of Anthos’ board and Global Head of Blackstone Life Sciences expressed pride in the firm’s role in launching and growing Anthos, adding, “We believe abelacimab has the potential to be a leader in the new class of Factor XI anticoagulants and are pleased to have Novartis as a committed partner to advance the development and commercialization of abelacimab for millions of patients at risk of strokes.”

Anthos is currently conducting multiple Phase 3 clinical trials, with data expected in the second half of 2026. While Novartis holds a small minority equity stake in Anthos, the company has not disclosed the exact size of this investment.

The Future Forbes Realty Global Properties

Tesla’s China-Made EV Sales Surge 35% Amid Fierce Industry Rivalry

by THEFUTURE.TEAM

March 13, 2026

Tesla’s China-made electric vehicle sales rebounded in early 2026, with combined deliveries for January and February rising more than 35% to 127,728 units on an adjusted basis. The increase follows seasonal adjustments related to the mid-February Lunar New Year and reflects renewed momentum for Tesla’s Shanghai Gigafactory. The facility supplies vehicles both to China’s domestic market and to export destinations across Europe and the Asia-Pacific region

China’s Robust EV Market

Data from the China Passenger Car Association (CPCA) indicates continued growth in China’s electric vehicle market despite intensifying competition among manufacturers. Although Tesla’s deliveries increased during the period, the company still trails Chinese automaker BYD in overall market share. BYD has strengthened its position through new battery technologies, including the Blade battery, which is designed to support significantly faster charging and improved safety.

Competitive Dynamics And Global Footprint

Production at Tesla’s Shanghai facility remains one of the largest sources of EV output globally. However, BYD overtook Tesla as the world’s largest electric vehicle manufacturer in 2025, supported by strong overseas expansion and a broader product portfolio. Tesla continues to rely on exports from Shanghai to support sales growth in international markets. Recent data has also shown rising vehicle registrations across several European countries, indicating sustained demand despite increasing competition.

Emerging Competitors And Market Shifts

Competition in China’s EV market has intensified as domestic manufacturers expand their offerings. Automakers such as Geely and Xiaomi are gaining market share by introducing vehicles with competitive pricing and advanced features. In February, one Geely model outsold vehicles from both Tesla and BYD in China, while Xiaomi’s YU7 SUV surpassed Tesla’s Model Y to become one of the country’s top-selling vehicles. The CPCA expects finalized sales data for March to provide further insight into market trends following the Lunar New Year period, which typically includes new model launches and increased production activity.